????麥克森公司將購買Rite Aid公司

????高居《財富》美國500強排行榜(Fortune 500)第14名的公司將收購位列第113名的公司,。仿制藥行業(yè)已經迅速地整合鞏固,，這個行業(yè)主要的分銷商麥克森公司( McKesson Corp)正在尋求新的投資目標。但就在這家公司在歐洲掃貨之際,，它的美國競爭對手捷足先登,，紛紛與排名前兩位的美國連鎖藥店運營商沃爾格林( Walgreen)和CVS達成收購協(xié)議。分析師表示,，作為剩下的局外人,，公司(Rite Aid)與麥克森公司有可能結為連理。“如果我是來愛德的話,，看到最大的兩個競爭對手在仿制藥零售領域攜手獲得了更好的交易,，我或許會嘗試跟進，”FBR資本市場公司(FBR Capital Markets)的湯姆?加盧奇這樣說道,。麥克森已經否認了該公司有收購美國零售商的意向,，但同時又說，它“似乎是最合乎邏輯的合作伙伴,，”如果不是徑直收購的話,。

????概率: 20%。

????McKesson will buy Rite Aid

????No. 14 on the Fortune 500 buys No. 113. The generic-drug industry has been quickly consolidating, and major distributor McKesson Corp. (MCK, Fortune 500) is pursuing new ventures. But while it went shopping in Europe, its American competitors called dibs on the top two U.S. pharmacy chains, striking purchasing deals with Walgreen (WAG,Fortune 500) and CVS (CVS, Fortune 500). The odd men out, Rite Aid (RAD, Fortune 500) and McKesson, could become bedfellows, analysts say: "If I'm Rite Aid, seeing two of my biggest competitors partnering up for better deals on generics, I might be motivated to try and keep up," says Tom Gallucci of FBR Capital Markets. McKesson has denied interest in a U.S. retailer, but "seems like the most logical partner," he says -- if not outright buyer.

????Odds: 20%.